CytomX Therapeutics Inc Total Liabilities

Latest as of June 2026: $79.16 Million USD

CytomX Therapeutics Inc total liabilities. Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has total liabilities worth $79.16 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of CytomX Therapeutics Inc to evaluate the company's liquid asset resilience ratio.

Total Liabilities of CytomX Therapeutics Inc (2013–2025)

Total liabilities of CytomX Therapeutics Inc from 2013 to 2025. This chart illustrates how CytomX Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of CytomX Therapeutics Inc to see how much of total assets are deployed in long-term investments.

CytomX Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of CytomX Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
AQUILA PART PROD COM RO:AQ	Romania	RON907.82 Million
Bichamp Cutting Technology Hunan Co Ltd SHE:002843	China	CN¥1.08 Billion
Hangzhou Anysoft Information Technology Co Ltd SHE:300571	China	CN¥4.16 Billion
Tae Kwang Corporation KQ:023160	Korea	₩71.20 Billion
Duta Pertiwi Tbk JK:DUTI	Indonesia	Rp2.46 Trillion
Clientele JSE:CLI	South Africa	ZAC14.17 Billion
Unizyx Holding Corp TW:3704	Taiwan	NT$16.61 Billion
SWS Hemodialysis Care Co. Ltd. A SHG:688410	China	CN¥349.56 Million

Liability Composition Analysis (2013–2025)

This chart breaks down CytomX Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CytomX Therapeutics Inc balance sheet assets.

Liquidity & Leverage Metrics

CytomX Therapeutics Inc Total Liabilities Ratios Explained

CytomX Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	9.36	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.21	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CytomX Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CytomX Therapeutics Inc (2013–2025)

The table below shows the annual total liabilities of CytomX Therapeutics Inc from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	$52.56 Million	-56.56%
2024-12-31	$120.99 Million	-51.46%
2023-12-31	$249.24 Million	-28.10%
2022-12-31	$346.64 Million	+38.64%
2021-12-31	$250.03 Million	-31.77%
2020-12-31	$366.44 Million	+26.28%
2019-12-31	$290.17 Million	-11.05%
2018-12-31	$326.23 Million	-0.46%
2017-12-31	$327.75 Million	+171.65%
2016-12-31	$120.65 Million	+69.58%
2015-12-31	$71.15 Million	-53.07%
2014-12-31	$151.60 Million	+159.32%
2013-12-31	$58.46 Million	--

About CytomX Therapeutics Inc

NASDAQ:CTMX USA Biotechnology

Market Cap

$475.02 Million

Market Cap Rank

#12137 Global

#3073 in USA

Share Price

$2.18

Change (1 day)

-2.24%

52-Week Range

$2.18 - $6.75

All Time High

$34.22